OncoMatch/Clinical Trials/NCT05558007
Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Is NCT05558007 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tadalafil 5mg and BZ371A for erectile dysfunction following radical prostatectomy.
Treatment: Tadalafil 5mg · BZ371A — To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Prior therapy
Must have received: radical prostatectomy
RP due to prostate cancer without metastasis; RP performed less than 60 days before the screening visit
Must have received: phosphodiesterase type 5 inhibitor (tadalafil)
Continuous use of 5mg Tadalafil from the 30th up to the 60th day after RP
Cannot have received: radiation therapy
Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy
Cannot have received: hormone therapy
Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy
Cannot have received: male hormone
Current male hormone use
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify